Board Appointment

Fulcrum Pharma PLC
06 January 2005


For immediate release                                             6 January 2005

                               Fulcrum Pharma plc
                          ('Fulcrum' or 'the Company')

                               Board Appointment


Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcing
services company, is pleased to announce the appointment of Dr Bruce McCreedy,
the Chief Executive Officer of Fulcrum's US subsidiary, to the Company's Board.

His appointment to the Board underlines the growing importance to Fulcrum of the
US market, where the Company is experiencing its fastest growth and is focussing
investment.

Dr McCreedy joined Fulcrum in June 2002 as Chief Executive Officer of Fulcrum
Pharmaceutical Developments, Inc, Fulcrum's US subsidiary based in Research
Triangle Park, North Carolina. Under Dr McCreedy's capable stewardship the
subsidiary, which is a key element in Fulcrum's growth strategy, has performed
ahead of target in its second year of operations.

Dr McCreedy, who holds a PhD from Wake University School of Medicine, North
Carolina, has more than seventeen years' experience of drug development,
executive management and business operations. This includes experience in both
public and private companies, licensing, M&A plus public and private financings.

Prior to joining Fulcrum he held positions including Associate Vice President of
Infectious Diseases and Clinical Trials with Roche Biomedical Laboratories (now
Laboratory Corporation of America), Vice President of Clinical Virology and
Diagnostics with Triangle Pharmaceuticals, and Chief Executive Officer of
TherapyEdge, Inc., a company he co-founded as a spin-off from Triangle
Pharmaceuticals.

Dr McCreedy joined Fulcrum's Board on the 1 January 2005.


Professor Sir Charles George, Chairman of Fulcrum Pharma, said: 'I am delighted
to welcome Dr McCreedy to the Company's Board. His appointment will reinforce
Fulcrum's progress in the US, the world's largest healthcare market and one
where our services are proving attractive to pharmaceutical and biotechnology
companies.'


For further information, please contact:

Fulcrum Pharma PLC                                            Tel: [phone]
Jon Court, CEO

Buchanan Communications                                       Tel: [phone]
Mary-Jane Johnson


Notes to Editors:

About Fulcrum Pharma

Fulcrum Pharma plc is an independent, drug development company that is the first
to offer global virtual drug development and strategic outsourcing services to
the pharmaceutical industry.  The Company has expertise in the design, execution
and delivery of drug development programmes and relies on state of the art
information technology and infrastructure in the supply of its services.

Through Fulcrum's services to its clients, the Directors believe that there is
the capacity to deliver products faster and more efficiently to the global
pharmaceutical market. Fulcrum does this by using its skills in the design of
drug programmes that deliver the necessary information for decision-making and
product registration. In so doing, Fulcrum works closely with its clients to
meet their strategic R&D goals.

Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange having successfully floated in March 2000.


                      This information is provided by RNS
            The company news service from the London Stock Exchange